Prevention of Nonsteroidal Anti-Inflammatory Drug-Induced Ulcer: Looking to the Future

Gastroenterology Clinics of North America

Volumn 38, Issue 2, 2009, Pages 315-332

  Fiorucci, Stefano ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Aspirin; CINOD; COX 2 inhibitors; Cyclooxygenase; Hydrogen sulfide; Naproxen; Nitric oxide

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTIINFLAMMATORY AGENT; ARTHROTEC; ATB 429; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ESOMEPRAZOLE PLUS NAPROXEN; ETORICOXIB; FLURBIPROFEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; HYDROGEN SULFIDE; IBUPROFEN; KETOPROFEN; LANSOPRAZOLE PLUS NAPROXEN; LUMIRACOXIB; NAPROXEN; NAPROXEN PLUS OMEPRAZOLE; NCX 4015; NITRIC OXIDE; NITRONAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARECOXIB; PN 100; PN 200; PN 400; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTON PUMP INHIBITOR; ROFECOXIB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VALDECOXIB;

ANEMIA; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; COLITIS; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DIVERTICULITIS; DRUG DOSE ESCALATION; DRUG SAFETY; DUODENUM ULCER; EVENING DOSAGE; GASTRODUODENAL EROSION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HIP OSTEOARTHRITIS; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY INJURY; KIDNEY PERFUSION; KNEE OSTEOARTHRITIS; LIVER FAILURE; MORNING DOSAGE; MUCOSA INFLAMMATION; NONHUMAN; OCCULT BLOOD; REVIEW; SIDE EFFECT; SMALL INTESTINE DISEASE; STOMACH INJURY; STOMACH MUCOSA LESION; STOMACH ULCER; STROKE; THROMBOEMBOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DRUG THERAPY, COMBINATION; FORECASTING; GASTROINTESTINAL DISEASES; HUMANS; PEPTIC ULCER; RISK ASSESSMENT; RISK FACTORS;

EID: 65549113804     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2009.03.001     Document Type: Review

References (53)

1. Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340 (1999) 1888-1899
2. FitzGerald G.A. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2 (2003) 879-890
3. FitzGerald G.A., and Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345 (2001) 433-442
4. Wallace J.L., and Granger D.N. The cellular and molecular basis of gastric mucosal defense. FASEB J 10 (1996) 731-740
5. Lanas A., Perez-Aisa M.A., Feu F., et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 100 (2005) 1685-1693
6. Lanas A., García Rodríguez L.A., Arroyo M.T., et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. [May 10, 2006, E-pub ahead of print]. Gut 55 (2006) 1731-1738
7. Lazzaroni M., Battocchia A., and Bianchi Porro G. Coxibs and non-selective NSAIDs in the gastrointestinal setting: what should patients and physicians do. Dig Liver Dis 39 (2007) 589-596
8. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 (1995) 241-249
9. Hawkey C.J., Karrasch J.A., Szczepanski L., et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338 (1998) 727-734
10. Yeomans N.D., Tulassay Z., Juhasz L., et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338 (1998) 719-726
11. Fiorucci S., and Del Soldato P. NO-aspirin: mechanism of action and gastrointestinal safety. Dig Liver Dis 35 Suppl 2 (2003) S9-19
12. Wallace J.L., Ignarro L.J., and Fiorucci S. Potential cardioprotective actions of nitric oxide-releasing aspirin. Nat Rev Drug Discov 1 (2002) 375-382
13. Fiorucci S., and Antonelli E. NO-NSAIDs: from inflammatory mediators to clinical readouts. Inflamm Allergy Drug Targets 5 (2006) 121-131
14. 2S -releasing NSAIDs, what lies beyond the horizon?. Dig liver Dis 39 (2007) 1043-1051
15. Wallace J.L., Caliendo G., Santagada V., et al. Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulphide-releasing diclofenac derivative in the rat. Gastroenterology 132 (2007) 261-271
16. Li L., Rossoni G., Sparatore A., et al. Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radic Biol Med 42 (2007) 706-719
17. Fiorucci S., Distrutti E., Cirino G., et al. The emerging roles of hydrogen sulphide in the gastrointestinal tract and liver. Gastroenterology 131 (2006) 259-271
18. Bias P., Buchner A., Klesser B., et al. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial. Am J Gastroenterol 99 4 (2004 Apr) 611-618
19. Fiorucci S., de Lima Jr. O.M., Mencarelli A., et al. Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology 123 (2002) 1598-1606
20. Bresalier R.S., Sandler R.S., Quan H., et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
21. Bombardier C., Laine L., Reicin A., et al. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
22. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
23. Schnitzer T.J., Burmester G.R., Mysler E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
24. Farkouh M.E., Kirshner H., Harrington R.A., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364 (2004) 675-684
25. Nussmeier N.A., Whelton A.A., Brown M.T., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (2005) 1081-1091
26. Johnsen S.P., Larsson H., Tarone R.E., et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 165 (2005) 978-984
27. Juni P., Nartey L., Reichenbach S., et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364 (2004) 2021-2029
28. Laine L., Connors L.G., Reicin A., et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124 2 (2003) 288-292
29. Goldstein J.L., Eisen G.M., Lewis B., et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 3 (2005) 133-141 10.1016/S1542-3565(04)00619-6
30. Wallace J.L., and Fiorucci S. A magic bullet for mucosal protection and aspirin is the trigger!. Trends Pharmacol Sci 24 7 (2003) 323-326
31. Fiorucci S., Distrutti E., de Lima O.M., et al. Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J 17 (2003) 1171-1173
32. Fiorucci S., Santucci L., Wallace J.L., et al. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci U S A 100 (2003) 10937-10941
33. Murad F. Shattuck lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med 355 19 (2006) 2003-2011
34. Wallace J.L., Keenan C.M., and Granger D.N. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Phys 259 (1990) G462-G467
35. Santucci L., Fiorucci S., Di Matteo F.M., et al. Role of tumor necrosis factor alpha release and leukocyte margination in indomethacin-induced gastric injury in rats. Gastroenterology 108 2 (1995) 393-401
36. Wallace J.L., Reuter B., Cicala C., et al. A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol 257 (1994) 249-255
37. Wallace J.L., Reuter B., Cicala C., et al. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 107 (1994) 173-179
38. Stefano F., and Distrutti E. Cyclo-oxygenase (COX) inhibiting nitric oxide donating (CINODs) drugs: a review of their current status. Curr Top Med Chem 7 3 (2007) 277-282
39. Fiorucci S., Di Lorenzo A., Renga B., et al. Nitric oxide (NO)-releasing naproxen (HCT-3012[(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection. J Pharmacol Exp Ther 311 3 (2004) 1264-1271
40. Fiorucci S., Antonelli E., Santucci L., et al. Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology 116 (1999) 1089-1106
41. Fiorucci S., Santucci L., Gresele P., et al. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 124 (2003) 600
42. Fiorucci S., Mencarelli A., Distrutti E., et al. Nitric oxide regulates immune cell bioenergetic: a mechanism to understand immunomodulatory functions of nitric oxide-releasing anti-inflammatory drugs. J Immunol 173 (2004) 874-882
43. Hawkey C., Jones J.I., Atherton C.T., et al. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 52 (2003) 1537-1542
44. Nitronaproxen: AZD 3582, HCT 3012, Naproxen Nitroxybutylester, NO-Naproxen. Drugs R D 7 4 (2006) 262-266
45. Lohmander L.S., McKeith D., Svensson O., et al., STAR Multinational Study Group. Ann Rheum Dis 64 (2005) 449-456
46. Huledal G., Jonzon B., Malmenas M., et al. Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. Clin Pharmacol Ther 77 (2005) 437-450
47. Schnitzer T.J., Kivitz A.J., Lipetz R.S., et al. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee. Arthritis Rheum 53 (2005) 827-837
48. 2S be the third endogenous gaseous transmitter?. FASEB J 16 (2002) 1792-1798
49. Goubern M., Andriamihaja M., Nubel T., et al. Sulfide, the first inorganic substrate for human cells. FASEB J 21 (2007) 1699-1706
50. Distrutti E., Sediari L., Mencarelli A., et al. Evidence that hydrogen sulphide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J Pharmacol Exp Ther 316 (2006) 325-335
51. Distrutti E., Sediari L., Mencarelli A., et al. 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1, 2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulphide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther 319 (2006) 447-458
52. Zanardo R.C., Brancaleone V., Distrutti E., et al. Hydrogen sulphide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J 20 (2006) 2118-2120
53. Fiorucci S., Orlandi S., Mencarelli A., et al. Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br J Pharmacol 150 (2007) 996-1002